IBM is an autoimmune disease that causes patients to gradually lose muscle function. Credit: andreas160578 from Pixabay.

Abcuro has commenced a registrational Phase ll/lll trial of ABC008 for the treatment of inclusion body myositis (IBM).

ABC008 is an anti-KLRG1 antibody that has been designed to selectively reduce highly cytotoxic T cells without harming regulatory and central memory T cells.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

IBM is an autoimmune disease where highly cytotoxic T cells continuously attack muscle tissue, thereby causing patients to gradually lose muscle function, such as loss of grip, dexterity and mobility.

In a Phase l study, Abcuro observed potent, durable, and dose-dependent reduction of CD8+KLRG1+ T cells, the most highly cytotoxic T cells.

The dose levels of the Phase ll/lll study showed 97% depletion of blood target cells at 28 days after injection.

See Also:

This trial will include over 200 patients across 30 sites worldwide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The randomised, double-blind, placebo-controlled, parallel multicentre trial will be carried out in three phases.

Abcuro chief medical officer Jeffrey Wilkins said: “This registrational Phase ll/lll trial represents an important milestone for patients with IBM.

“It builds upon the compelling proof of mechanism observed with ABC008 to potently and selectively deplete highly cytotoxic T cells which attack and destroy muscle tissue in IBM, without affecting protective T cell populations.

“This approach differentiates ABC008 from broad T cell depleters whose use has been limited by adverse effects associated with broad immune-cell depletion.”